Washington’s 9.9% income tax is now law. Get the Tax Planning Guide →
Sign in
Sign in
Anti-Dilution

Anti-Dilution Provisions: What Every Startup Founder Needs to Understand Before Their Series A

By Joe Wallin,

Published on Apr 9, 2026   —   19 min read

Series ATerm SheetsStartup LawVenture CapitalFundraisingDown Round
Legal documents representing corporate formation

Summary

Anti-dilution provisions are among the most consequential — and least understood — terms in venture financing. Here's how they work, what they mean for your cap table, and what to negotiate.

Anti-Dilution Provisions: What Every Startup Founder Needs to Understand Before Their Series A

I've represented hundreds of founders through their first institutional fundraises, and if there's one provision in a term sheet that consistently gets glossed over, it's anti-dilution protection. Founders skim past it, investors emphasize it, and by the time you're three years in and raising a down round, you realize you've either protected yourself brilliantly or handed your investors a loaded gun pointed at your equity.

In This Guide

Anti-dilution provisions are one of those things that seem abstract until they're not. When your company's valuation drops from $50 million to $30 million in a Series B, suddenly these provisions aren't theoretical—they're the difference between maintaining meaningful ownership or watching your stake shrink by 20, 30, or even 50 percent without the company issuing a single new share to you. And in some cases, anti-dilution can actually make your share count go backwards.

That's not exaggeration. That's exactly what anti-dilution does. Let me walk you through what these provisions actually are, how they work, and what you need to negotiate before you sign your Series A term sheet.

What Anti-Dilution Protection Really Is

Let's start with the basics. Dilution in a startup happens naturally—it's inevitable and often necessary. When you issue new shares to employees, offer options to key hires, or raise capital at a higher valuation, the ownership percentages of existing shareholders shrink. If you owned 50 percent of your company and it had 1 million shares outstanding, and then you issue another 1 million shares, your ownership drops to 25 percent. The company didn't shrink; your slice got smaller because the pie got bigger.

That's normal dilution. It happens all the time, and founders understand it. What founders often don't understand is what happens when dilution occurs at a lower valuation than what previous investors paid.

Here's where anti-dilution comes in. When an investor puts money into your Series A at, say, $10 per share, they're betting on a certain future return. They own equity at that price point. But what if, two years later, your Series B happens at only $6 per share? That earlier investor's equity is underwater relative to their expectation. The whole company is being valued lower, which means their investment was overpriced in the first place.

Investors don't like surprises like that. So in the Series A term sheet, they insert an anti-dilution provision: a protection that says, "If the company ever issues shares at a lower price than what we paid, we get to adjust our terms so we're not damaged by that down round."

From an investor perspective, this makes sense. They put in money, took risk, and they don't want to be punished if the company stumbles. From a founder perspective, anti-dilution is where you get punished if the company stumbles—because it reduces your ownership percentage even though you didn't cause the down round and the company didn't issue new shares to dilute you directly.

The Two Main Types: Full Ratchet vs. Weighted Average

There are essentially two flavors of anti-dilution: full ratchet and weighted average. The difference between them is enormous, and this is where most founders get hurt because they don't read their preferred stock terms carefully.

Full Ratchet: The Investor's Dream, the Founder's Nightmare

Full ratchet anti-dilution is aggressive. Here's how it works: if a new round of financing happens at a lower price per share than the investor paid, their conversion price is retroactively adjusted all the way down to the new, lower price. Full stop.

Let's say a Series A investor buys shares at $10 per share. A few years later, you're raising Series B at $6 per share. Under full ratchet, that Series A investor's shares are retroactively repriced at $6 per share, as if they invested at that price from day one.

Why is this brutal? Because it creates massive dilution to common shareholders—which includes you and your employees. The investor gains additional shares without putting in additional money. The pie doesn't grow, but their slice grows, which means everyone else's slice shrinks.

I'll give you a concrete example. Let's say you have a cap table that looks like this going into a down round:

Pre-Series B (Down Round Scenario):

  • Series A Investor: 1,000,000 shares at $10 per share ($10M investment)
  • Common Stock (you and employees): 2,000,000 shares
  • Total outstanding: 3,000,000 shares
  • Your ownership: 66.7%
  • Series A ownership: 33.3%

Now you raise Series B at $6 per share. Before any new shares are issued, full ratchet kicks in. The Series A investor's conversion price of $10 is adjusted down to $6. This means their 1,000,000 shares are now "worth" $6 instead of $10, so they get additional shares to make up the difference.

The adjustment is calculated as: Original Shares × (Original Price / New Price) = New Share Count

Series A investor's new share count: 1,000,000 × ($10 / $6) = 1,666,667 shares

The Series A investor now has 666,667 additional shares, issued for free, because of the down round. And then they invest new capital at the Series B round in addition to this. Your ownership dropped from 66.7% to 54.5% without you or anyone else making that happen—it was the down round alone.

This is why full ratchet is controversial. It's a sledgehammer. It's also relatively rare in today's market because founders have gotten savvy about pushing back on it. But it still appears, especially in smaller rounds or from investors who don't know better (or who do and are being aggressive). If you see full ratchet in a term sheet, you should negotiate hard to remove it or narrow it.

Weighted Average: The Standard Anti-Dilution Approach

Weighted average anti-dilution is the middle ground, and it's become the market standard for most Series A investments. It's less draconian than full ratchet but still provides investor protection.

With weighted average, the investor's conversion price is adjusted based on a formula that takes into account both the old investment price and the new, lower price, weighted by the number of shares involved in each round. The formula looks like this:

New Conversion Price = Old Conversion Price × [(Outstanding Shares Before Round + (Investment Amount / Old Conversion Price)) / (Outstanding Shares Before Round + (Investment Amount / New Price))]

Or in shorthand: NCP = OCP × (A + B) / (A + C), where A = shares outstanding before the round, B = new investment dollars divided by the old conversion price, and C = new investment dollars divided by the new (lower) price. Since the old price is higher, B is smaller than C, which makes the ratio less than 1 and pulls the conversion price down.

There are actually two versions of weighted average: broad-based and narrow-based. Broad-based includes all shares outstanding when calculating the denominator (common stock, options, convertible debt, etc.). Narrow-based only includes preferred stock. Broad-based is more founder-friendly because the larger denominator results in a smaller adjustment to the investor's conversion price.

Let me show you how this plays out with concrete numbers. Using the same scenario:

Pre-Series B Down Round (Same as Before):

  • Series A Investor: 1,000,000 shares at $10 per share ($10M investment)
  • Common Stock (you and employees): 2,000,000 shares
  • Total outstanding: 3,000,000 shares

Now Series B happens at $6 per share, and you're raising $12M. That means 2,000,000 new shares are issued at the Series B round.

Under broad-based weighted average, the formula is:

New Conversion Price = Old Conversion Price × (A + B) / (A + C)

Where A = fully diluted shares outstanding before the new round, B = the number of shares the new investment would have purchased at the old conversion price (New Investment / Old Conversion Price), and C = the number of shares actually issued in the new round (New Investment / New Price).

The key insight is that B is always smaller than C in a down round (because the old price is higher, the same dollar amount buys fewer shares at the old price). This makes the fraction (A + B) / (A + C) less than 1, which pulls the conversion price downward.

Let’s plug in our numbers:

A = 3,000,000 (total shares outstanding before the round)

B = $12M / $10 = 1,200,000 (shares the new money would buy at the old Series A price)

C = $12M / $6 = 2,000,000 (shares actually issued in the Series B)

New Conversion Price = $10 × (3,000,000 + 1,200,000) / (3,000,000 + 2,000,000) = $10 × 4,200,000 / 5,000,000 = $10 × 0.84 = $8.40

So the Series A investor’s conversion price adjusts from $10 down to $8.40. They get some downward adjustment, but it’s far less aggressive than full ratchet. When their preferred shares eventually convert to common stock, they’ll convert at the new $8.40 price instead of $10, giving them approximately 1,190,476 common shares ($10M / $8.40) instead of the original 1,000,000—about 190,000 additional shares. Under full ratchet, by comparison, they’d have gotten roughly 667,000 additional shares.

For common shareholders, your dilution under broad-based weighted average in a down round is roughly proportional to the amount of new capital being raised. You get diluted, but it's "normal" dilution from new shares, plus a modest adjustment from the anti-dilution provision. It's not ideal, but it's far more manageable than full ratchet.

Narrow-based weighted average is similar to broad-based, except the denominator only counts preferred stock (Series A and Series B), not common stock or options. Because the denominator is smaller, the ratio deviates more from 1, resulting in a larger downward adjustment to the investor’s conversion price—meaning more dilution to common shareholders. Broad-based is more founder-friendly than narrow-based because the larger denominator produces a smaller adjustment.

If you’re going to agree to weighted average (which you probably will), push hard for broad-based rather than narrow-based. Most Series A investors will accept broad-based without pushback, and it’s become the market standard.

What Triggers Anti-Dilution? Understanding Down Rounds

Anti-dilution provisions only kick in when the company issues shares at a lower price than what the prior investors paid. But what exactly constitutes a "lower price issuance"? This is important because the definition of what counts as a triggering event determines when you're going to get hit.

Generally, the triggering event is any issuance of equity securities at a price below the Series A conversion price. This includes:

Obvious triggering events: Series B at a lower valuation, Series C at a lower valuation, convertible notes converted at a discount, secondary offerings of common stock at a discount.

Less obvious events: Stock option grants when the exercise price is set significantly below the Series A price. If you're issuing options with an exercise price of $2 when Series A was at $10, that can trigger anti-dilution because it's effectively a low-price issuance.

That's why most term sheets have detailed carve-outs and exceptions. Standard exceptions that do NOT trigger anti-dilution include:

Stock option and employee equity plans: Issuances pursuant to an approved equity plan at fair market value (usually determined by an independent 409A valuation) don't trigger anti-dilution. This is essential—otherwise you couldn't hire anyone without triggering investor protection clauses.

Strategic partnerships and acquisitions: If you issue equity as part of an acquisition or strategic partnership, this often has a carve-out. However, watch the definition carefully. If you're issuing equity for consideration that's mostly below FMV, it might still trigger anti-dilution.

Splits and recapitalizations: Stock splits, reverse splits, and other recapitalizations don't trigger anti-dilution. Good—you need this flexibility for future capital structures.

Conversions of debt: Converting convertible notes or SAFEs at terms that were negotiated at their inception typically don't trigger anti-dilution, or they trigger it only to the extent the conversion price is below prior preferred pricing.

The devil is in the details here. When you're reviewing a term sheet, look at the specific carve-out language. I've seen founders get burned because a provision they thought was a carve-out actually had limitations buried in it.

Pay-to-Play and Anti-Dilution: How They Interact

Pay-to-play provisions are closely related to anti-dilution, and founders often confuse the two. Pay-to-play means that if an investor doesn't participate in a future down round at the same percentage ownership they currently have, they lose their anti-dilution protection or some other right. It's a punishment for not doubling down on the company.

Here's the logic from the investor's perspective: "We invested at $10 per share in Series A. If Series B is at $6 per share and we don't participate, why should we get anti-dilution protection? We're not backing the company at the lower price."

Pay-to-play can actually be favorable to common shareholders because it means investors who don't believe in the company at lower valuations lose their anti-dilution protection. This limits the damage to your equity. But pay-to-play can also hurt founders because it creates pressure on existing investors to participate in down rounds, which can either prevent the down round from happening (if investors won't commit capital) or encourage a particularly destructive one (if you need to go lower to get participation).

Pay-to-play is common in institutional Series A rounds but less common in smaller rounds or from founder-friendly investors. When you see it in a term sheet, understand that it works both ways: it limits anti-dilution damage from non-participating investors, but it might make down rounds harder to execute.

How Anti-Dilution Appears in Your Actual Charter

Here's something that trips up a lot of founders: anti-dilution provisions in a term sheet look very different from how they appear in your actual certificate of incorporation. The term sheet might say something like "broad-based weighted average anti-dilution protection." Your actual charter says something like this:

"In the event the Company issues shares at a price below the Conversion Price, the Conversion Price shall be adjusted to equal the product of the Conversion Price then in effect multiplied by a fraction..."

And then there's a complex formula that goes on for a full page. Most founders never look at their certificate of incorporation. They review the term sheet, negotiate based on the summary language, and then sign the charter without understanding exactly what they agreed to.

This is a mistake. Before you sign anything, get a copy of the charter that will contain the anti-dilution language and read it carefully. Have your lawyer walk you through it. The term sheet summary language is binding, but the actual operative language is in the charter, and the devil is in those details.

I've seen founders negotiate successfully on a term sheet, only to discover that the charter language implemented their negotiated deal differently than they understood it. By then, it's often too late to change without annoying the investor.

Negotiating Anti-Dilution: What Founders Can Actually Push Back On

Here's what I tell founders: anti-dilution protection for investors is a given in almost every Series A. It's not something you're going to eliminate entirely unless you're raising from angels or founders' funds. But you absolutely can negotiate the type and scope of anti-dilution.

These are the things you should push for:

Weighted average instead of full ratchet: This is your #1 priority. Full ratchet is brutal, and most investors will accept weighted average without much pushback. If an investor insists on full ratchet, that's a red flag about their willingness to be reasonable. You should push back hard or consider walking away.

I've negotiated hundreds of Series A's, and I can count on one hand the number where full ratchet was the final deal. It happens, but it's usually with unsophisticated investors or in situations where the founder has no leverage (which is rare). Full ratchet is negotiable.

Broad-based rather than narrow-based: Some investors may push for narrow-based weighted average, which uses a smaller denominator and produces a larger downward adjustment to their conversion price—worse for you. Push for broad-based, which includes all shares outstanding in the calculation and results in a smaller, more proportionate adjustment. The difference is meaningful in a down round, and most investors will accept broad-based without much pushback.

Strong carve-outs: The carve-out for equity grants is essential, but make sure it's written clearly. You want to be able to grant options and restricted stock to employees at fair market value without triggering anti-dilution. Make sure the carve-out covers: (a) grants under an approved equity plan, (b) at prices determined by an independent 409A valuation, (c) granted in good faith for services. Don't let the investor narrow this language unnecessarily.

Clarity on what constitutes a "lower price" issuance: Push for a clear definition. Are convertible notes that convert at a discount treated as a triggering event? What about warrant exercises at below-market prices? The more specific you can get here, the easier it is to manage your cap table without accidentally triggering anti-dilution.

A reasonable definition of "shares outstanding": For weighted average calculations, what counts toward the denominator? Make sure you negotiate this carefully. Broad-based is better than narrow-based from your perspective, so if the investor is willing to use a broad-based definition, take it.

These are reasonable negotiation points. Most investors expect some back-and-forth on anti-dilution language. What you shouldn't expect to negotiate:

You're probably not going to eliminate anti-dilution entirely. You're probably not going to get a carve-out for all future rounds (some carve-outs for future fundraising exist, but they're rare and usually apply only to rounds above a certain size). You probably won't get anti-dilution to apply only in "catastrophic" down rounds or at certain percentage drops—that's not how these provisions work.

Focus your negotiation energy on the items listed above. Those are the things that have real impact and that investors are flexible on.

How Anti-Dilution Actually Affects Your Cap Table in a Down Round

Let me walk you through what a real down round looks like with anti-dilution. This is the scenario every founder should model before they sign a Series A term sheet.

Original Cap Table (at Series A close):

  • Founder/Employees (Common): 5,000,000 shares
  • Series A Investor: 2,500,000 shares at $10/share ($25M investment)
  • Total outstanding: 7,500,000 shares
  • Founder ownership: 66.7%
  • Series A ownership: 33.3%

Series B Down Round, 2 Years Later at $6/share (Weighted Average, Broad-Based):

You're raising $30M at $6/share. That's 5,000,000 new shares.

Using the same broad-based weighted average formula from earlier:

A = 7,500,000 (total shares outstanding before the round)

B = $30M / $10 = 3,000,000 (shares the new money would buy at the old Series A price)

C = $30M / $6 = 5,000,000 (shares actually issued in the Series B)

New Conversion Price = $10 × (7,500,000 + 3,000,000) / (7,500,000 + 5,000,000) = $10 × 10,500,000 / 12,500,000 = $10 × 0.84 = $8.40

So the Series A investor’s conversion price drops from $10 to $8.40. When their preferred shares convert to common, they’ll receive $25M / $8.40 = approximately 2,976,190 common shares instead of the original 2,500,000—about 476,190 additional shares from the anti-dilution adjustment.

Series B investor invests $30M at $6/share and gets 5,000,000 new shares.

Post-Series B Cap Table:

  • Founder/Employees (Common): 5,000,000 shares
  • Series A (at $8.40 conversion price): approximately 2,976,190 shares on an as-converted basis
  • Series B: 5,000,000 shares at $6/share ($30M investment)
  • Total on as-converted basis: approximately 12,976,190 shares
  • Founder ownership: approximately 38.5%
  • Series A ownership: approximately 22.9%
  • Series B ownership: approximately 38.5%

Your ownership dropped from 66.7% to approximately 38.5%. Without any anti-dilution adjustment, the Series A investor would have kept their original 2,500,000 shares, and your ownership would have been 5,000,000 / 12,500,000 = 40%. So the anti-dilution adjustment cost you an additional 1.5 percentage points of ownership—meaningful but manageable under broad-based weighted average.

If this had been full ratchet, your ownership would have dropped even further. Under full ratchet, the Series A investor’s conversion price drops all the way to $6, giving them $25M / $6 = 4,166,667 shares on conversion. Total as-converted shares would be 5,000,000 + 4,166,667 + 5,000,000 = 14,166,667, and your ownership would be about 35.3%—compared to 38.5% under broad-based weighted average. That’s why the type of anti-dilution matters.

The Relationship Between Anti-Dilution and Liquidation Preferences

Here's something most founders don't understand until they're reading a term sheet: anti-dilution doesn't exist in isolation. It works hand-in-hand with liquidation preferences, and the combination can be devastating in a down exit.

Liquidation preferences determine the order in which proceeds from a sale or liquidation are distributed. A typical preference is "1x non-participating preferred," which means the preferred investor gets back their investment first, then any remaining proceeds are distributed on a pro-rata basis.

But here's the problem: anti-dilution adjusts the number of preferred shares, which directly affects the liquidation preference calculation. If anti-dilution has increased the Series A investor's share count, their liquidation preference is now based on a larger number of shares, which means they get more of the proceeds in a sale.

So in a down round followed by a sale: (1) anti-dilution reduces the number of common shares and increases the preferred shares, and then (2) liquidation preferences use the new share counts to distribute proceeds. The combination can wipe out common shareholders entirely in a modest exit.

This is why modeling down-round scenarios before you sign a Series A is crucial. You need to understand not just how anti-dilution affects your percentage ownership, but how it affects your actual proceeds in various exit scenarios.

Common Mistakes Founders Make with Anti-Dilution

I see the same mistakes over and over, and they're preventable.

Not reading the actual charter language: You negotiate on the term sheet and then sign the charter without comparing the two. The charter language should match the term sheet, but I've seen gaps. Read your charter before you sign. Have your lawyer walk you through it.

Not modeling down-round scenarios: Founders assume good outcomes and don't think through what anti-dilution means if things go sideways. Before you sign a Series A term sheet, run through a scenario where Series B happens at 40% of your Series A valuation. What does that do to your ownership? To your proceeds in a 2x return scenario? Understanding this changes how you negotiate.

Accepting full ratchet when they don't have to: I see this regularly with first-time founders who don't have legal representation and are unsure how much they can push back. Full ratchet is not standard. It's negotiable. If you're offered full ratchet, push back. If the investor won't move, reconsider the deal.

Confusing anti-dilution with dilution from new fundraising: Some founders think anti-dilution somehow prevents normal dilution from new rounds. It doesn't. You're still going to get diluted when you raise Series B and Series C. Anti-dilution is an adjustment on top of that. The two are separate phenomena.

Not understanding the carve-outs: Many founders accidentally trigger anti-dilution because they grant options or issue shares for partnerships without realizing it's a triggering event. Understand the carve-outs in your term sheet. Know what does and doesn't count as a lower-price issuance.

Over the past few years, we've seen the market push toward more founder-friendly anti-dilution language, primarily because founders have gotten smarter about negotiating it and because the venture ecosystem is more competitive for good deals.

Full ratchet is essentially dead in institutional Series A investing. It still pops up occasionally in smaller rounds, from less experienced investors, or in situations where a founder has no leverage. But if you're raising from a reputable VC fund, full ratchet is not an expectation.

Broad-based weighted average has become the market standard, which is a move away from narrow-based. This is actually better for founders because the broader denominator results in less aggressive anti-dilution adjustments. Most institutional investors will agree to broad-based without pushback, and many prefer it because it's perceived as fairer.

Pay-to-play provisions have become less common in Series A rounds, though they still show up in later-stage financing and in smaller rounds where investors are more conservative. When they do appear, they're often negotiated to cover only a portion of an investor's stake, rather than an all-or-nothing proposition.

The reason for these shifts is primarily founder sophistication. Ten years ago, founders had fewer resources for understanding term sheets. Now, there are standardized templates, resources like the SAFE, and enough founder discourse around term sheet language that investors can't get away with aggressive anti-dilution provisions unless the founder is truly inexperienced.

Practical Advice: What to Negotiate and What to Accept

Here's my practical playbook for founders dealing with anti-dilution in a Series A term sheet:

Ask for broad-based weighted average as your opening position. This is the most founder-friendly standard approach because the larger denominator (which includes all shares, options, and convertible instruments) results in the smallest downward adjustment to the investor’s conversion price. Most institutional investors will accept broad-based without pushback—it’s become the market standard.

If the investor insists on narrow-based, understand the trade-off. Narrow-based uses a smaller denominator (only preferred stock), which means the conversion price adjusts more aggressively in a down round—worse for you and your employees. It’s not ideal, but it’s still far better than full ratchet. If you can’t get broad-based, narrow-based weighted average is an acceptable fallback, not a deal-breaker.

Never accept full ratchet without extreme pushback. I mean this. If an investor insists on full ratchet, either get your lawyer to walk them through why it's problematic and why they should move to weighted average, or seriously consider whether this is an investor you want to work with for the next 5-7 years. Full ratchet is aggressive and it signals something about how the investor thinks about risk and founder relationships.

Negotiate hard on carve-outs. The carve-out for equity grants is essential. Make sure it's broad enough to cover all of your employee equity grants without restriction. If the investor tries to limit the carve-out (like, "only equity grants below $1M aggregate value" or "only at 409A valuation plus 10%"), push back. Your ability to compensate employees is crucial to your company's success, and it shouldn't be constrained by anti-dilution mechanics.

Get clarity on what counts as a triggering event. Ask your lawyer to walk through examples: convertible notes converting at a discount, warrant exercises, spin-off company equity, strategic partnership equity. What triggers anti-dilution and what doesn't? Get examples in writing, or at least a clear statement of the principle that guides the definition. This prevents disputes later.

Model the down-round scenario before you sign. Take the Series A investment amount and the valuation. Now model what Series B looks like if the valuation is 60%, 50%, and 40% of your Series A valuation. How much do you get diluted? How does anti-dilution affect your proceeds in a 2x or 3x exit? This exercise will inform your negotiation and you'll understand what you're agreeing to.

Don't make anti-dilution the hill you die on if everything else is good. Anti-dilution is important, but if you've negotiated weighted average and decent carve-outs, and the valuation, terms, and investor partnership are all good, don't torpedo the deal because you want a slightly better anti-dilution provision. Get the big stuff right and then accept reasonable anti-dilution language.

Final Thoughts

Anti-dilution provisions are one of the most important things you'll agree to in a Series A, but they're not the most important. Fair valuation, investor partnership quality, and company strategy matter more. But within the context of a good deal, you absolutely need to negotiate thoughtfully on anti-dilution.

The key is understanding what you're agreeing to before you sign. Read the term sheet language carefully. Have a lawyer explain how weighted average actually works with your specific numbers. Model a down-round scenario. Ask questions about carve-outs. And then make informed decisions about what to negotiate and what to accept.

Anti-dilution is just one protection in an investor's toolkit, but it's a powerful one. Make sure you understand it before you hand it over.

Navigating equity, cap tables, and investor terms is one of the most important things you'll do as a founder. If you're raising capital or want to make sure your cap table is structured correctly, I'd be happy to discuss your specific situation. Schedule a free introductory call with me—we can talk through your equity strategy and make sure you're set up for success.

Author profile

Joe Wallin

Share on Facebook Share on Linkedin Share on Twitter Send by email

Keep reading

Subscribe to the newsletter

Practical updates on QSBS, Washington taxes, equity compensation, and startup law — for founders, investors, and startup employees.

Subscribe